| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 4.03▲ | 4.01▲ | 4.00▲ | 3.91▲ | 4.03▲ |
| MA10 | 4.02▲ | 3.99▲ | 3.93▲ | 4.05▲ | 4.35▼ |
| MA20 | 4.00▲ | 3.91▲ | 3.84▲ | 4.20▼ | 4.38▼ |
| MA50 | 3.99▲ | 3.86▲ | 3.99▲ | 4.44▼ | 3.83▲ |
| MA100 | 3.93▲ | 4.00▲ | 4.06▼ | 4.44▼ | 3.63▲ |
| MA200 | 3.84▲ | 4.07▼ | 4.35▼ | 3.95▲ | 3.03▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.005▲ | 0.015▲ | 0.040▲ | -0.023▼ | -0.105▼ |
| RSI | 74.227▲ | 68.163▲ | 62.984▲ | 45.290▼ | 47.790▼ |
| STOCH | 82.639▲ | 87.763▲ | 89.987▲ | 44.697 | 33.153 |
| WILL %R | 0.000▲ | 0.000▲ | 0.000▲ | -49.091 | -64.331 |
| CCI | 195.152▲ | 124.409▲ | 115.231▲ | -52.679 | -112.832▼ |
|
Tuesday, February 03, 2026 03:48 AM
Arbutus Biotech (ABUS) heads to a key March Moderna LNP patent trial as imdusiran HBV milestones drive value—get the latest data, cash runway and outlook.
|
|
Monday, January 12, 2026 09:00 AM
Arbutus Biopharma (ABUS) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 09/02/26 | 3.89 | 4.06 | 3.795 | 4.06 | 2,181,944 |
| 06/02/26 | 3.84 | 3.90 | 3.67 | 3.84 | 2,563,374 |
| 05/02/26 | 3.88 | 3.915 | 3.62 | 3.67 | 1,607,762 |
| 04/02/26 | 4.10 | 4.125 | 3.86 | 3.88 | 1,124,112 |
| 03/02/26 | 4.40 | 4.42 | 3.87 | 4.11 | 3,267,089 |
| 02/02/26 | 4.13 | 4.60 | 3.50 | 4.39 | 5,303,082 |
| 30/01/26 | 4.10 | 4.17 | 4.065 | 4.13 | 886,069 |
| 29/01/26 | 4.14 | 4.19 | 4.085 | 4.13 | 674,412 |
| 28/01/26 | 4.17 | 4.245 | 4.06 | 4.14 | 1,197,144 |
| 27/01/26 | 4.05 | 4.185 | 4.05 | 4.16 | 648,344 |
|
|
||||
|
|
||||
|
|